IMR Press / FBL / Volume 10 / Issue 2 / DOI: 10.2741/1659

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Epidermal growth factor receptor: is a novel therapeutic target for pancreatic cancer?
Show Less
1 Cancer Research Unit, Department of Veterans Affairs Medical Center, 4801 East Linwood Boulevard, Kansas City, MO 64128-2226, USA
2 Saint Luke’s Hospital and University of Missouri, Kansas City, MO

Academic Editor: Sushanta K. Banerjee

Front. Biosci. (Landmark Ed) 2005, 10(2), 1763–1767;
Published: 1 May 2005
(This article belongs to the Special Issue Growth factors and cancer)

Expression of epidermal growth factor receptors (EGFR) is exaggerated in pancreatic adenocarcinoma and activation of EGFR appears to have an important role in the growth and differentiation of this and in other tumors. Therefore, blockade or inactivation of EGFR by monoclonal antibodies or by tyrosine kinase inhibitors has significant potential as an effective anti-cancer therapy. One of the very recent significant developments in the field of molecular biology involves the use of antisense of EGFR or EGFR gene silencing in pancreatic cancer cells as a potential targeted therapy for patients with pancreatic adenocarcinoma.

Tyrosine Kinase Inhibitors
Back to top